Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma

Table 2 Immune monitoring summary and clinical outcomes of patients who produced a measureable immune response

Dose (mg)	Patient	HLA Type	HLA/A*0101 Tetramer⁺	CD8+ IFNγ+	Phenotype Tetramer⁺CD8⁺T cells*
0.2	Tyr-1	A0101	-	-
	Tyr-2	A1101	ND	-
	Tyr-3	A01	ND	-
0.5	Tyr-4	A0101	-	-
	Tyr-5	A0101	-	-
	Tyr-6	A2501	ND	-
1.5	Tyr-8	A2402	ND	-
	Tyr-9	A0101	+	-	CCR7^low,CD45RA^low, CD27^int, CD28^int
	Tyr-11	A0101	-	-
	Tyr-12#	A02	ND	ND
	Tyr-13	A2402	ND	-
	Tyr-14	A0301/A2402	ND	-
	Tyr-16#	A0101	ND	ND
	Tyr-18	A0101	-	-
	Tyr-19	A0101	-	-
	Tyr-20#	A0101	ND	ND
	Tyr-21	A03	ND	-
	Tyr-22	A0101	-	-
	Tyr-23	A0101	-	-
	Tyr-24	A0101	-	+
	Tyr-25	A0101	-	+
	Tyr-26	A0101	+	+	CCR7^low,CD45RA^low, CD27^int, CD28^low
	Tyr-27	A0101	+	-	CCR7^low,CD45RA^low, CD27^int, CD28^int
	Tyr-28	A0101	+	-	CCR7^low,CD45RA^low, CD27^int, CD28^int

* Low = 0–30%, intermediate (int) =30–60%, and high = 60–100% of cells that are tetramer positive. # Patient Tyr-12, 16 and 20 did not finish vaccine protocol. ND = not done. “+” = Patients scored positive for tetramer-reactive CD8⁺ T cell or Tyr-reactive CD8⁺IFN-γ⁺ T cell response; “-” = Patients scored negative for tetramer-reactive CD8⁺ T cell or Tyr-reactive CD8⁺IFN-γ⁺ T cell response.